IgA nephropathy

20 trials 6 recruiting MedDRA PT
20 Registered trials
6 Recruiting
14 Unique sponsors
13 Unique IMPs
17 Commercial trials
Drug classes (ATC)
— ATC code not specified 16
L Oncology (ATC L) 3
P Parasitology (ATC P) 1
H Endocrinology (ATC H) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 7 substances
Monoclonal antibody (immune) 1 substance
Complement inhibitor (C5) 1 substance
Receptor fusion protein 1 substance
Monoclonal antibody 1 substance
Monoclonal antibody (rat) 1 substance
Corticosteroid 1 substance
Phase III: 9 Phase II/III: 1 Phase II: 5 Phase III/IV: 3 Phase I: 2 Phase I (Other): 1

Filter these 20 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 20 trials

Phase III

9 trials
  • Biogen Idec Research Limited Commercial
    FELZARTAMAB
    2024-519345-30-00 11 countries 2025 n=201
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    ISIS 696844
    2022-502102-32-00 7 countries 2023 n=87
    Ended
  • Novartis Pharma AG Commercial
    IPTACOPAN
    2024-511067-29-00 12 countries 2021 n=102 Orphan
    Ended
  • Novartis Pharma AG Commercial
    ZIGAKIBART
    2024-519638-22-00 8 countries n=69 Orphan
    Pending
  • Otsuka Pharmaceutical Development And Commercialization Inc. Commercial
    SIBEPRENLIMAB
    2022-500079-30-00 12 countries 2022 n=99 Orphan
    Ended
  • Takeda Development Center Americas Inc. Commercial
    MEZAGITAMAB
    2025-520825-19-00 12 countries 2025 n=83
    Recruiting
  • Travere Therapeutics Inc. Commercial
    SPARSENTAN
    2023-505495-30-00 11 countries 2019 n=162 Orphan
    Ended
  • Centre Hospitalier Universitaire De Saint Etienne Academic
    HYDROXYCHLOROQUINE SULFATE
    2024-512653-25-00 1 country 2025 n=334
    Recruiting
  • Fondazione Schena Centro Europeo Della Ricerca Sulle Malattie Renali Academic
    METHYLPREDNISOLONE SODIUM SUCCINATE
    2024-517861-18-00 1 country n=432
    Pending

Phase II/III

1 trial
  • Otsuka Pharmaceutical Development & Commercialization Inc. Commercial
    SIBEPRENLIMAB
    2023-507233-19-00 12 countries 2023 n=96 Orphan
    Recruiting

Phase II

5 trials
  • Alexion Pharmaceuticals Inc. Commercial
    VEMIRCOPAN
    2023-504825-38-00 3 countries 2022 n=35
    Ended
  • Alexion Pharmaceuticals Inc. Commercial
    RAVULIZUMAB
    2023-507977-16-00 7 countries 2021 n=87
    Ended
  • Novartis Pharma AG Commercial
    ATRASENTAN HYDROCHLORIDE
    2023-503828-13-00 1 country 2023 n=10 Orphan
    Ended
  • Travere Therapeutics Inc. Commercial
    SPARSENTAN
    2023-505497-14-00 6 countries 2021 n=27 Orphan
    Recruiting
  • Vera Therapeutics Inc. Commercial
    ATACICEPT
    2024-518465-10-00 6 countries 2025 n=124 Orphan
    Recruiting

Phase III/IV

3 trials
  • Novartis Pharma AG Commercial
    IPTACOPAN
    2023-508690-92-00 13 countries 2021 n=100 Orphan
    Ended
  • Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre Academic
    RAVULIZUMAB
    2024-512154-24-00 1 country 2023 n=15
    Ended
  • Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre Academic
    RAVULIZUMAB
    2024-512154-24-00 1 country 2023 n=15
    Ended

Phase I

2 trials
  • Pfizer Inc. Commercial
    IMP not specified
    2024-519215-33-00 1 country 2025 n=92
    Ended
  • Walden Biosciences Inc. Commercial
    IMP not specified
    2024-516446-18-00 1 country n=84
    Pending

Phase I (Other)

1 trial
  • Takeda Development Center Americas Inc. Commercial
    IMP not specified
    2024-516743-34-00 2 countries 2022 n=3
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 4 Phase III/IV, Phase II, Phase III 0
Takeda Development Center Americas Inc. Commercial 2 Phase I (Other), Phase III 1
Alexion Pharmaceuticals Inc. Commercial 2 Phase II 0
Travere Therapeutics Inc. Commercial 2 Phase II, Phase III 1
Institut De Recerca Biomedica De Lleida Fundacio Dr. Pifarre Academic 2 Phase III/IV 0
Pfizer Inc. Commercial 1 Phase I 0
Walden Biosciences Inc. Commercial 1 Phase I 0
Otsuka Pharmaceutical Development & Commercialization Inc. Commercial 1 Phase II/III 1
Vera Therapeutics Inc. Commercial 1 Phase II 1
Biogen Idec Research Limited Commercial 1 Phase III 1
F. Hoffmann-La Roche AG Commercial 1 Phase III 0
Otsuka Pharmaceutical Development And Commercialization Inc. Commercial 1 Phase III 0
Centre Hospitalier Universitaire De Saint Etienne Academic 1 Phase III 1
Fondazione Schena Centro Europeo Della Ricerca Sulle Malattie Renali Academic 1 Phase III 0
New trials by year
2019
1
2021
4
2022
3
2023
5
2025
5
← All indication landscapes